Here are five key points:
1. An increasing geriatric population and government funding will also boost the market.
2. The Americas is experiencing the highest demand for spine biologics and captures the largest market share.
3. Between 2016 and 2026, North America will see growth in the spine biologics segment due to an increasing population, growing awareness of new technologies and rising per capita income of hospitals and the population.
4. The procedures’ costliness and availability of substitute products will hinder market growth.
5. Alphatech Spine, Medtronic, Zimmer Biomet, Globus Medical, Exactech, RTI Biologics, Small Bone Innovations, Stryker, Amedica, K2M, NuVasive, Precision Spine and TranS1 dominate the market.
More articles on devices:
31 orthopedic & spine devices receive FDA 510(K) clearance in June
Medtronic’s VariLoc system launches in China, 9 more countries to come in 2016: 5 key notes
Global medical robotics market to hit $17.9B by 2022 — 8 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
